Chardan Capital Comments on Immuneering FY2025 Earnings

Immuneering Co. (NASDAQ:IMRX) – Stock analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Immuneering in a research report issued on Monday, March 24th. Chardan Capital analyst G. Livshits expects that the company will post earnings of ($1.65) per share for the year. Chardan Capital currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.86) per share.

A number of other research firms have also recently issued reports on IMRX. Morgan Stanley cut Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 target price on shares of Immuneering in a research note on Friday, March 21st.

Immuneering Stock Down 3.0 %

IMRX opened at $1.64 on Thursday. The business’s fifty day simple moving average is $1.78 and its 200 day simple moving average is $2.00. Immuneering has a 52 week low of $1.00 and a 52 week high of $3.83. The stock has a market cap of $58.85 million, a PE ratio of -0.83 and a beta of -0.32.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.16).

Institutional Trading of Immuneering

Several institutional investors have recently added to or reduced their stakes in IMRX. Corsair Capital Management L.P. bought a new stake in shares of Immuneering in the 3rd quarter valued at about $25,000. HighTower Advisors LLC increased its stake in Immuneering by 21.4% in the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock worth $132,000 after purchasing an additional 9,400 shares during the period. Rockefeller Capital Management L.P. bought a new stake in Immuneering in the fourth quarter valued at approximately $390,000. XTX Topco Ltd boosted its stake in shares of Immuneering by 177.2% during the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock valued at $72,000 after purchasing an additional 20,871 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Immuneering in the fourth quarter worth approximately $47,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.